Program konačnih razlika četvrtog reda točnosti za simulaciju rasprostiranja SH-vala u heterogenom viskoelastičnom sredstvu

This article presents a staggered grid time-domain finite-difference (FD) program for the simulation of sH-wave propagation in a viscoelastic heteroge¬neous medium. The incorporation of realistic damping in FD program is based on a rheological model widely known as generalized maxwell body (gmB-EK). The accuracy of implementation of realistic damping is validated by comparing the numerically computed frequency dependent quality factors and phase velocity with the same computed using gmB-EK rheological model and the Futterman’s relationship. The accuracy was also validated by comparing the numerically com¬puted soil amplification at resonance frequency for different damping with the analytical solutions. The stability and grid dispersion are also studied in details.Prikazan je program konačnih razlika (FD) na razmaknutoj mreži u vremenskoj domeni za simulaciju rasprostiranja sH-vala u viskoelastičnom heterogenom sredstvu. Uključivanje realističnog prigušenja u program temelji se na reološkom modelu poznatom kao generalizirano maxwellovo tijelo (gmB-EK). Valjanost implementiranog prigušenja je potvrđena usporedbom numerički dobivenih frekventno ovisnih kvalitativnih faktora i fazne brzine s onima izračunatim gmB-EK reološkim modelom i korištenjem Futter¬manove relacije. Točnost je potvrđena i usporedbom numerički izračunate amplifikacije tla pri rezonantnoj frekvenciji za različito prigušenje s analitičkim rješenjima. stabilnost i disperzija mreže su također detaljno istraženi

Vécu psychologique des patients trois mois après la sortie de réanimation

International audienc

Enquête sur la distribution du crédit aux agriculteurs dans le département du Cantal : résultats pour la période 1970-1975

Diffusion du document : INRA Station d'Economie et Sociologie rurales 65 rue de Saint-Brieuc 35042 Rennes Cedex (FRA)Cette note se réduit à une présentation commenté des premiers résultats de l'enquête menée dans le cantal. La période étudiée couvre les années 1970 à 1975. La situation structurelle des exploitations est saisie au départ par les données du RGA puis par celles de l'EPEXA en 1975. La méthode employée consiste à utiliser pour le département du Cantal, un sous-échantillon EPEXA (le taux moyen de sondage est de 1/50) dont les exploitations sont analysées tant du point de vue de leur évolution structurelle que de celui de leur endettement. Les données sur ce point ont été recueillies par l'enquête auprès de la Caisse Régionale du Cantal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Déclinaisons tonales du Bas-Ouellé.

Vinay J.P. Déclinaisons tonales du Bas-Ouellé. In: Journal de la Société des Africanistes, 1941, tome 11. pp. 223-224

Déclinaisons tonales du Bas-Ouellé.

Vinay J.P. Déclinaisons tonales du Bas-Ouellé. In: Journal de la Société des Africanistes, 1941, tome 11. pp. 223-224

Phonétique et langues africaines

Vinay J.P. Phonétique et langues africaines. In: Journal de la Société des Africanistes, 1941, tome 11. pp. 95-113

Quelques observations supplémentaires sur le parler judéo-espagnol de Salonique

Crews Cynthia M., Vinay J.P. Quelques observations supplémentaires sur le parler judéo-espagnol de Salonique. In: Bulletin Hispanique, tome 41, n°3, 1939. pp. 209-235